This "Boring" Dividend King Is Quietly Turning Into a Growth Machine
Key Points
J&J’s stock has rallied over the past 12 months.
It’s a solid safe-haven stock, but it could have more upside than its peers.
- 10 stocks we like better than Johnson & Johnson ›
Johnson & Johnson (NYSE: JNJ) has raised its dividend annually for 64 consecutive years. That makes it a Dividend King, the elite title given to stocks that have raised their payouts for at least 50 straight years, but it's often considered a boring, defensive play. Yet over the past 12 months, J&J's stock has rallied more than 50%.
Image source: Getty Images.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Why did J&J's stock rally?
J&J streamlined its operations by divesting its slower-growth businesses over the past few years. Today, it operates two core businesses: its Innovative Medicine segment, which sells its pharmaceutical products; and its MedTech segment, which sells medical devices.
Most of its revenue and growth comes from its Innovative Medicine segment, which sells higher-margin, patent-protected drugs for cancer, autoimmune diseases, cardiopulmonary conditions, and neurological disorders. Over the next few years, J&J plans to expand its newer drugs -- including Tremfya for autoimmune disorders and Icotye for psoriasis -- to offset its loss of exclusivity for Stelara (its multi-billion-dollar psoriasis drug) in early 2025.
J&J also still has a deep bench of potential blockbuster drugs, and its MedTech business should grow steadily to serve the aging population. Analysts expect J&J's EPS to decline 15% in 2026 as it absorbs the loss from Stelara, recognizes some on-time accounting expenses, and incurs higher expenses on its new drug launches. But they expect its EPS to grow 11% in 2027 and 7% in 2028 as it laps those non-recurring charges and grows its core businesses again.
J&J's stock still looks reasonably valued at 26 times this year's earnings; it pays a forward yield of 2.3%, and it should continue to grow faster as a streamlined company. Therefore, this Dividend King might have more upside than some of its dusty old peers.
Should you buy stock in Johnson & Johnson right now?
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $580,872!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,219,180!*
Now, it’s worth noting Stock Advisor’s total average return is 1,016% — a market-crushing outperformance compared to 197% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 16, 2026.
Leo Sun has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
Recommended Articles
